# Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

> **NCT02064725** · PHASE2 · UNKNOWN · sponsor: **Kevelt AS** · enrollment: 8 (actual)

## Conditions studied

- Recurrent or Persistent Endometrial Carcinoma

## Interventions

- **DRUG:** Sodium cridanimod

## Key facts

- **NCT ID:** NCT02064725
- **Lead sponsor:** Kevelt AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2018-01
- **Final completion:** 2018-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064725, "Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02064725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*